Biggest changeWe incurred a net loss for the years ended December 31, 2022, 2021 and 2020 of $40,763,573 (of which $15,775,553 was related to non-cash stock-based compensation primarily due to our LTIP), $40,377,160 (of which $17,302,833 was related to non-cash stock-based compensation primarily due to our LTIP), and $17,952,172 in 2020, respectively.
Biggest changeWe incurred a net loss for the years ended December 31, 2023, 2022 and 2021 of $50,149,077 (of which $12,711,084 was related to non-cash stock-based compensation primarily due to our LTIP; $4,358,062 was related to our excess and obsolescence impairment charge to inventory; $2,136,993 was related to a goodwill and intangible impairment charge for our Moviynt acquisition in 2022; and $1,574,000 was related to a bad debt reserve), $40,763,573 (of which $15,775,553 was related to non-cash stock-based compensation primarily due to our LTIP), and $40,377,160 in 2021 (of which $17,302,833 was related to non-cash stock-based compensation primarily due to our LTIP), respectively.
If we are not the primary beneficiary in a VIE, we account for the investment or other variable interests in a VIE in accordance with applicable GAAP.
If we are not the primary beneficiary in a VIE, we account for the investment or other variable interests in a VIE in accordance with other applicable GAAP.
The fair market value of our common stock on the date of each option grant is determined based on the most recent quoted sales price on our primary trading stock exchange, currently the NASDAQ Capital Market. For stock options awards under the Company's LTIP (Long-term Incentive Plan), options vest upon the achievement of certain equity market conditions and performance-based milestones.
The fair value of our common stock on the date of each option grant is determined based on the most recent quoted sales price on our primary trading stock exchange, currently the NASDAQ Capital Market. For stock options awards under the Company's LTIP (Long-term Incentive Plan), options vest upon the achievement of certain equity market conditions and performance-based milestones.
Selling and marketing costs consist of trade show costs, advertising, sales samples, travel costs, sales staff compensation costs including stock-based compensation expense, consulting fees, public relations agency fees, website costs and sales commissions paid to full-time staff and outside consultants. Year Ended % of Year Ended % of Dollar % Increase December 31, 2022 Total Sales December 31, 2021 Total Sales Change (Decrease) Selling and Marketing $ 8,078,538 68 % $ 6,118,929 46 % $ 1,959,609 32 % Selling and marketing costs for the year ended December 31, 2022, increased by $1,959,609 or 32%, as compared to the same period in 2021.
Selling and marketing expenses consist of trade show costs, advertising, sales samples, travel costs, sales staff compensation costs including stock-based compensation expense, consulting fees, public relations agency fees, website costs and sales commissions paid to full-time staff and outside consultants. Year Ended % of Year Ended % of Dollar % Increase December 31, 2022 Total Sales December 31, 2021 Total Sales Change (Decrease) Selling and Marketing $ 8,078,538 68 % $ 6,118,929 46 % $ 1,959,609 32 % Selling and marketing expenses for the year ended December 31, 2022, increased by $1,959,609 or 32%, as compared to the same period in 2021.
General and administrative costs include professional fees, investor relations (IR) costs, salaries and related stock compensation, travel costs, office and rental costs. Year Ended % of Year Ended % of Dollar % Increase December 31, 2022 Total Sales December 31, 2021 Total Sales Change (Decrease) General and Administrative $ 21,038,562 178 % $ 22,502,833 171 % $ (1,464,271) (7) % General and administrative costs for the year ended December 31, 2022 decreased by $1,464,271 or 7%, as compared to the same period in 2021.
General and administrative expenses include professional fees, investor relations (IR) costs, salaries and related stock compensation, travel costs, office and rental costs. Year Ended % of Year Ended % of Dollar % Increase December 31, 2022 Total Sales December 31, 2021 Total Sales Change (Decrease) General and Administrative $ 21,038,562 178 % $ 22,502,833 171 % $ (1,464,271) (7) % General and administrative expenses for the year ended December 31, 2022 decreased by $1,464,271 or 7%, as compared to the same period in 2021.
To date, all such contracts have been less than one calendar year in duration. Product Warranty Warranty obligations are generally incurred in connection with the sale of our products. The warranty period for these products is generally one year and up to 18 months for certain distributors. Customers may also purchase an additional twelve (12) month extended warranty.
To date, all such contracts have been less than one calendar year in duration. Product Warranty Warranty obligations are generally incurred in connection with the sale of our products. The warranty period for these products is generally one year and up to eighteen (18) months for certain distributors. Customers may also purchase an additional twelve (12) month extended warranty.
The overall increase in other income was primarily the result of an increase of $1,342,068 in investment income resulting from the recent rise in interest rates earned on the Company’s excess cash period over period; a $466,705 gain recorded for an employee 44 Table of Contents retention credit refund claim that was filed with the IRS on November 10, 2022; and a decrease of $94,371 in income and other taxes, partially offset by an increase of $37,393 in foreign exchange losses.
The overall increase in other income was primarily the result of an increase of $1,342,068 in investment income resulting from the recent rise in interest rates earned on the Company’s excess cash period-over-period; a $466,705 gain recorded for an employee 46 Table of Contents retention credit refund claim that was filed with the IRS on November 10, 2022; and a decrease of $94,371 in income and other taxes, partially offset by an increase of $37,393 in foreign exchange losses.
There was a decrease in total sales for the year ended December 31, 2022, from those in 2021 of $1,329,051 or 10%.
There was a decrease in total sales for the year ended December 31, 2022, from those achieved in 2021 of $1,329,051 or 10%.
With respect to our Smart Glasses and AR products, we are focused on the enterprise, industrial, medical and commercial markets.
With respect to our Smart Glasses and AR products, we are focused on the enterprise, defense, industrial, medical and commercial markets.
As of December 31, 2022 and 2021, deferred revenue associated with our expected returns was immaterial. The Company collects and remits sales taxes in certain jurisdictions and reports revenue net of any associated sales taxes. Revenue from engineering consulting and other services is recognized at the time the services are rendered.
As of December 31, 2023 and 2022, deferred revenue associated with our expected returns was immaterial. The Company collects and remits sales taxes in certain jurisdictions and reports revenue net of any associated sales taxes. Revenue from engineering consulting and other services is recognized at the time the services are rendered.
Software development expenses to determine technical 43 Table of Contents feasibility before final development and ongoing maintenance are not capitalized and are included in research and development costs. Year Ended % of Year Ended % of Dollar % Increase December 31, 2022 Total Sales December 31, 2021 Total Sales Change (Decrease) Research and Development $ 12,676,688 107 % $ 11,674,954 89 % $ 1,001,734 9 % Research and development costs for the year ended December 31, 2022, increased by $1,001,734 or 9%, as compared to the same period in 2021.
Software development expenses to determine 45 Table of Contents technical feasibility before final development and ongoing maintenance are not capitalized and are included in research and development expenses. Year Ended % of Year Ended % of Dollar % Increase December 31, 2022 Total Sales December 31, 2021 Total Sales Change (Decrease) Research and Development $ 12,676,688 107 % $ 11,674,954 89 % $ 1,001,734 9 % Research and development expenses for the year ended December 31, 2022, increased by $1,001,734 or 9%, as compared to the same period in 2021.
Cost of product revenues and engineering services are comprised of materials, components, labor, warranty costs, freight costs, manufacturing overhead, software royalties, and the non-cash depreciation for our tooling and manufacturing equipment and amortization of software development costs related to the production of our products and rendering of engineering services.
Cost of product revenues and engineering services are comprised of materials, components, labor, warranty costs, freight costs, manufacturing overhead, software royalties, the depreciation for our tooling and manufacturing equipment, and amortization of software development costs related to the production of our products and rendering of engineering services.
Recent Accounting Pronouncements Refer to Note 1 41 Table of Contents Results of Operations for Fiscal Years Ended December 31, 2022 and December 31, 2021 The following table compares the Company’s consolidated statements of operations data for the years ended December 31, 2022 and 2021. Year Ended December 31, Dollar % Increase 2022 2021 Change (Decrease) Sales: Sales of Products $ 10,505,763 $ 12,784,600 $ (2,278,837) (18) % Sales of Engineering Services 1,330,119 380,333 949,786 250 % Total Sales 11,835,882 13,164,933 (1,329,051) (10) % Cost of Sales: Cost of Sales - Products Sold 8,737,852 9,709,268 (971,416) (10) % Cost of Sales - Inventory Reserve for Obsolescence 290,405 519,950 (229,545) (44) % Cost of Sales - Depreciation and Amortization 799,317 1,321,467 (522,150) (40) % Cost of Sales - Engineering Services 525,182 45,758 479,424 1,048 % Total Cost of Sales 10,352,756 11,596,443 (1,243,687) (11) % Gross Profit 1,483,126 1,568,490 (85,364) (5) % Gross Profit % 13 % 12 % Operating Expenses: Research and Development 12,676,688 11,674,954 1,001,734 9 % Selling and Marketing 8,078,538 6,118,929 1,959,609 32 % General and Administrative 21,038,562 22,502,833 (1,464,271) (7) % Depreciation and Amortization 1,788,584 988,104 800,480 81 % Loss on Fixed Asset Disposal 35,350 183,614 (148,264) (81) % Impairment of Patents and Trademarks 97,675 80,163 17,512 22 % Loss from Operations (42,232,271) (39,980,107) (2,252,164) 6 % Other Income (Expense): Investment Income 1,395,579 53,511 1,342,068 2,508 % Income and Other Taxes (212,997) (307,368) 94,371 (31) % Foreign Exchange Loss (180,589) (143,196) (37,393) 26 % Employee Retention Credit Refund 466,705 — 466,705 NM Total Other Income (Expense), Net 1,468,698 (397,053) 1,865,751 (470) % Net Loss $ (40,763,573) $ (40,377,160) $ (386,413) 1 % 42 Table of Contents Sales.
There were no provisions for income taxes in 2023 or 2022. 43 Table of Contents Results of Operations for Fiscal Years Ended December 31, 2022 and December 31, 2021 The following table compares the Company’s consolidated statements of operations data for the years ended December 31, 2022 and 2021. Year Ended December 31, Dollar % Increase 2022 2021 Change (Decrease) Sales: Sales of Products $ 10,505,763 $ 12,784,600 $ (2,278,837) (18) % Sales of Engineering Services 1,330,119 380,333 949,786 250 % Total Sales 11,835,882 13,164,933 (1,329,051) (10) % Cost of Sales: Cost of Sales - Products Sold 8,737,852 9,709,268 (971,416) (10) % Cost of Sales - Inventory Reserve for Obsolescence 290,405 519,950 (229,545) (44) % Cost of Sales - Depreciation and Amortization 799,317 1,321,467 (522,150) (40) % Cost of Sales - Engineering Services 525,182 45,758 479,424 1,048 % Total Cost of Sales 10,352,756 11,596,443 (1,243,687) (11) % Gross Profit 1,483,126 1,568,490 (85,364) (5) % Gross Profit % 13 % 12 % Operating Expenses: Research and Development 12,676,688 11,674,954 1,001,734 9 % Selling and Marketing 8,078,538 6,118,929 1,959,609 32 % General and Administrative 21,038,562 22,502,833 (1,464,271) (7) % Depreciation and Amortization 1,788,584 988,104 800,480 81 % Loss on Fixed Asset Disposal 35,350 183,614 (148,264) (81) % Impairment of Patents and Trademarks 97,675 80,163 17,512 22 % Loss from Operations (42,232,271) (39,980,107) (2,252,164) 6 % Other Income (Expense): Investment Income 1,395,579 53,511 1,342,068 2,508 % Income and Other Taxes (212,997) (307,368) 94,371 (31) % Foreign Exchange Loss (180,589) (143,196) (37,393) 26 % Employee Retention Credit Refund 466,705 — 466,705 NM Total Other Income (Expense), Net 1,468,698 (397,053) 1,865,751 (470) % Net Loss $ (40,763,573) $ (40,377,160) $ (386,413) 1 % 44 Table of Contents Sales.
We consolidate VIEs when we are the primary beneficiary. We are the primary beneficiary of a VIE when we have the power to direct activities that most significantly affect the economic performance of the VIE and have the obligation to absorb the majority of their losses or benefits.
We are the primary beneficiary of a VIE when we have the power to direct activities that most significantly affect the economic performance of the VIE and have the obligation to absorb the majority of their losses or benefits.
The Company accounts for its longer-term development contracts, which to date have all been firm fixed-priced contracts, on 39 Table of Contents the percentage-of-completion method, whereby income is recognized as work on contracts progresses, but estimated losses on contracts in progress are charged to operations immediately. The percentage-of-completion is determined using the cost-to-cost method.
The Company accounts for its longer-term development contracts, which to date have all been firm fixed-priced contracts, on the percentage-of-completion method, whereby income is recognized as work on contracts progresses, but estimated losses on contracts in progress are charged to operations immediately. The percentage-of-completion is determined using the cost-to-cost method.
Total other income was $1,468,698 for the year ended December 31, 2022, as compared to other expense of $397,053 in the same period in 2021, an increase of $1,865,851.
Total other income was $1,468,698 for the year ended December 31, 2022, as compared to other expense of $397,053 in the same period in 2021, an increase of $1,865,751.
The Company recognizes revenue from these product sales as performance obligations are satisfied and transfer of control to the customer has occurred, typically upon physical shipment. Revenue is recognized in the amount that the Company expects to receive in exchange from the sale of our products.
Product sales represent the majority of the Company’s revenue. The Company recognizes revenue from these product sales as performance obligations are satisfied and transfer of control to the customer has occurred, typically upon physical shipment. Revenue is recognized in the amount that the Company expects to receive in exchange from the sale of our products.
Our research and development costs consist primarily of compensation costs for personnel, related stock-based compensation expenses, third-party services, purchase of research supplies and materials, and consulting fees related to research and development.
Our research and development expenses consist primarily of compensation costs for personnel, related stock-based compensation expenses, third-party services, purchases of research supplies and materials, and consulting fees related to research and development.
The fair value of options granted under this program were calculated by using a Monte Carlo simulation for the equity market condition tranches and the Black-Scholes-Merton option pricing method for the performance-based tranches. The equity market condition awards are expensed over their derived service periods, which is an output of the Monte Carlo model.
The fair 38 Table of Contents value of options granted under this program was calculated by using a Monte Carlo simulation for the equity market condition tranches and the Black-Scholes-Merton option pricing method for the performance-based tranches. The equity market condition awards are expensed over their derived service periods, which is an output of the Monte Carlo model.
We believe our technology, intellectual property portfolio and position in the marketplace give us a leadership position in AR and Smart Glasses products, waveguide optics, micro LEDs and display engine technology.
We believe our technology, intellectual property portfolio and position in the marketplace give us a leadership position in AR and Smart Glasses products, waveguide optics, microLEDs and display engine technology.
The critical accounting policies, judgments and estimates that we believe have the most significant effect on our financial statements are: ● Valuation of inventories; 37 Table of Contents ● Variable interest entities; ● Business combinations: ● Carrying value of long-lived assets, goodwill and other intangible assets; ● Software development costs; ● Revenue recognition; ● Product warranty; ● Stock-based compensation; and ● Income taxes.
The critical accounting policies, judgments and estimates that we believe have the most significant effect on our financial statements are: ● Valuation of inventories; 35 Table of Contents ● Going Concern ● Variable interest entities; ● Carrying value of long-lived assets, goodwill and other intangible assets; ● Software development costs; ● Revenue recognition; ● Product warranty; ● Stock-based compensation; and ● Income taxes.
Our research and development costs consist primarily of compensation costs for personnel, related stock-based compensation expenses, third-party services, purchase of research supplies and materials, and consulting fees related to research and development.
Our research and development expenses consist primarily of compensation costs for personnel, including non-cash stock-based compensation expenses, third-party services, purchases of research supplies and materials, and consulting fees related to research and development.
The write-down and obsolescence provision for finished goods and components totaled $290,405, $519,950 and $1,273,835 for the years ended December 31, 2022, 2021 and 2020, respectively. These provisions are included in Cost of Sales on the Consolidated Statements of Operations.
The write-down and obsolescence provision for finished goods and components totaled $4,358,062, $290,405 and $519,950 for the years ended December 31, 2023, 2022 and 2021, respectively. These provisions are included in Cost of Sales on the Consolidated Statements of Operations.
Manufacturing overhead costs, not already added in Cost of Sales, decreased by $184,545 or 8% for the year ended December 31, 2022 over the 2021 comparable period to 19% as a percentage of total sales as compared to 18% in 2021.
Manufacturing overhead costs, not already added in Cost of Sales, decreased by $817,194 or 34% for the year ended December 31, 2022 over the 2021 comparable period to 13% as a percentage of total sales as compared to 18% in 2021.
Our current liabilities are comprised principally of accounts payable, accrued expenses, licensing fee commitments, and operating lease right-of-use liabilities. Summary of Cash Flow: The following table summarizes our select cash flows for the years ended: December 31, December 31, December 31, 2022 2021 2020 Net Cash Provided by (used in) Operating Activities (24,521,082) (26,980,411) (13,964,053) Investing Activities (21,170,816) (4,852,452) (1,485,513) Financing Activities (1,948,032) 115,967,228 40,912,983 During the year ended December 31, 2022, we used $24,521,082 of cash for operating activities.
Our current liabilities are comprised principally of accounts payable, accrued expenses, licensing fee commitments, and operating lease right-of-use liabilities. Summary of Cash Flow: The following table summarizes our select cash flows for the years ended: December 31, December 31, December 31, 2023 2022 2021 Net Cash Provided by (used in) Operating Activities (26,277,824) (24,521,082) (26,980,411) Investing Activities (19,280,966) (21,170,816) (4,852,452) Financing Activities (449,561) (1,948,032) 115,967,228 During the year ended December 31, 2023, we used $26,277,824 of cash for operating activities.
The following table reflects the components of our cost of goods sold: Year Ended % of Year Ended % of Dollar % Increase December 31, 2022 Total Sales December 31, 2021 Total Sales Change (Decrease) Product Cost of Sales $ 6,815,981 58 % $ 7,832,397 59 % $ (1,016,416) (13) % Manufacturing Overhead - Unapplied 2,212,276 19 % 2,396,821 18 % (184,545) (8) % Depreciation and Amortization 799,317 7 % 1,321,467 10 % (522,150) (40) % Engineering Services Cost of Sales 525,182 4 % 45,758 0 % 479,424 1,048 % Total Cost of Sales 10,352,756 87 % 11,596,443 88 % (1,243,687) (11) % Gross Profit $ 1,483,126 13 % $ 1,568,490 12 % $ (85,364) (5) % For the year ended December 31, 2022, gross profit from total sales was $1,483,126 or 13% as compared to $1,568,490 or 12% in the same period in 2021.
The following table reflects the components of our cost of goods sold: Year Ended % of Year Ended % of Dollar % Increase December 31, 2022 Total Sales December 31, 2021 Total Sales Change (Decrease) Product Cost of Sales $ 7,448,630 63 % $ 7,832,397 59 % $ (383,767) (5) % Manufacturing Overhead - Unapplied 1,579,627 13 % 2,396,821 18 % (817,194) (34) % Depreciation and Amortization 799,317 7 % 1,321,467 10 % (522,150) (40) % Engineering Services Cost of Sales 525,756 4 % 45,758 0 % 479,424 1,048 % Total Cost of Sales 10,352,756 87 % 11,596,443 88 % (1,243,687) (11) % Gross Profit $ 1,483,126 13 % $ 1,568,490 12 % $ (85,364) (5) % For the year ended December 31, 2022 gross profit from total sales was $1,483,126 or 13% as compared to $1,568,490, or 12% in the same period in 2021.
In the event that it should be determined that all or part of a deferred tax asset in the future is more likely than not to be realized, an adjustment (reduction) of the valuation allowance would increase income to be recognized in the period such determination was made. 40 Table of Contents In addition, the calculation of our deferred taxes involves dealing with uncertainties in the application of complex tax regulations.
In the event that it should be determined that all or part of a deferred tax asset in the future is more likely than not to be realized, an adjustment (reduction) of the valuation allowance would increase income to be recognized in the period such determination was made.
Provision for Income Taxes . There were no provisions for income taxes in 2022 or 2021. Liquidity and Capital Resources Capital Resources: As of December 31, 2022, we had cash and cash equivalents of $72,563,943, a decrease of $47,639,930 from $120,203,873 as of December 31, 2021.
Provision for Income Taxes . There were no provisions for income taxes in 2022 or 2021. Liquidity and Capital Resources Capital Resources: As of December 31, 2023, we had cash and cash equivalents of $26,555,592, a decrease of $46,008,351 from $72,563,943 as of December 31, 2022.
For the year ended December 31, 2021, we used a total of $26,980,411 in cash for operating activities.
For the year ended December 31, 2022, we used a total of $24,521,082 in cash for operating activities.
For the year ended December 31, 2021, we used a total of $4,852,452 in cash for investing activities.
For the year ended December 31, 2022, we used a total of $21,170,816 in cash for investing activities.
For the years ended December 31, 2022 and 2021, we recorded a loss on fixed asset disposal of $35,350 and $183,614, respectively, upon the retirement of certain tooling and manufacturing equipment assets no longer in use. No loss on fixed asset disposal charges on tooling and equipment were recorded in 2020.
For the years ended December 31, 2023, 2022 and 2021, we recorded a loss on fixed asset disposal of nil, $35,350, and $183,614, respectively, upon the retirement of certain tooling and manufacturing equipment assets no longer in use. We perform a valuation of our patents and trademark assets when events or circumstances indicate their carrying amounts may be unrecoverable.
During the year ended December 31, 2022, we used $1,948,032 in net cash from financing activities, which included $2,005,744 for share repurchases under our Share Buyback Program that was announced on March 2, 2022, and partially offset by $57,712 in proceeds from the exercise of stock options.
During the year ended December 31, 2023, we used $449,561 in net cash from financing activities, which included $21,196 received for stock option exercises, which was offset by $470,757 expended for share repurchases under our Share Buyback Program that expired on March 2, 2023. For the year ended December 31, 2022, we used $1,948,032 in net cash for financing activities.
Selling and marketing costs consist of trade show costs, advertising, sales samples, travel costs, sales staff compensation costs including stock-based compensation expense, consulting fees, public relations agency fees, website costs and sales commissions paid to full-time staff and outside consultants. Year Ended % of Year Ended % of Dollar % Increase December 31, 2021 Total Sales December 31, 2020 Total Sales Change (Decrease) Selling and Marketing $ 6,118,929 46 % $ 4,039,772 35 % $ 2,079,157 51 % Selling and marketing costs for the year ended December 31, 2021, increased by $2,079,157 or 51% as compared to 2020.
Selling and marketing expenses consist of trade show costs, advertising, sales samples, travel costs, sales staff compensation costs including stock-based compensation expense, consulting fees, public relations agency fees, website costs and sales commissions paid to full-time staff and outside consultants. Year Ended % of Year Ended % of Dollar % Increase December 31, 2023 Total Sales December 31, 2022 Total Sales Change (Decrease) Selling and Marketing $ 12,711,800 105 % $ 8,078,538 68 % $ 4,633,262 57 % Selling and marketing expenses for the year ended December 31, 2023, increased by $4,633,262 or 57%, compared to the comparable period in 2022.
There was an increase in total sales for the year ended December 31, 2021 from those in 2020 of $1,583,437 or 14%.
There was an increase in total sales for the year ended December 31, 2023, from those achieved in 2022 of $293,257, or 2%.
The value of the remaining intellectual property, such as patents and trademarks, was valued (net of accumulated amortization) at $2,220,094 as of December 31, 2022, because management believes that this value is recoverable.
For the years ended December 31, 2023, 2022 and 2021, there was an impairment charge of $41,869, $97,675 and $80,163, respectively. The value of the remaining intellectual property, such as patents and trademarks, was valued (net of accumulated amortization) at $2,627,018 as of December 31, 2023, because management believes that this value is recoverable.
As a result, we recognize liabilities for uncertain tax positions based on the two-step process prescribed by GAAP.
In addition, the calculation of our deferred taxes involves dealing with uncertainties in the application of complex tax regulations. As a result, we recognize liabilities for uncertain tax positions based on the two-step process prescribed by GAAP.
The Company’s cash requirements are primarily for funding operating losses, working capital, research and development, capital expenditures, and license fee commitments.
The Company’s cash requirements are primarily for funding operating losses, working capital, research and development, capital expenditures, and license fee commitments. Our operations have historically been financed primarily through net proceeds from the sale of our equity securities.
For the year ended December 31, 2021, we received $115,967,228 in proceeds from financing activities, primarily from sales of our equity securities. 48 Table of Contents As of December 31, 2022, the Company does not have any current or long-term debt obligations outstanding other than licensing fee commitments totaling $11,500,000 related to the Atomistic Agreements described in Note 7 of the consolidated financial statements.
As of December 31, 2023, the Company does not have any current or long-term debt obligations outstanding other than licensing fee commitments totaling $1,000,000 related to the Atomistic Agreements described in Note 7 of the consolidated financial statements.
This program is in effect for one year, does not obligate the Company to acquire any particular amount of common stock and may be suspended or discontinued at any time at the Company’s sole discretion. Equity Compensation Plan Information The following table provides information about our equity compensation plan as of December 31, 2022. Number of Weighted Securities to Average be Issued Exercise Price Number of Upon Exercise of Securities of Outstanding Outstanding Remaining Options, Options, Available for Warrants and Warrants and Future Issuance Plan Category Rights Rights (1) Equity compensation plans approved by security holders 8,589,673 $ 15.34 1,495,760 Equity compensation plans not approved by security holders — — — Total 8,589,673 $ 15.34 1,495,760 (1) The amount appearing under “Number of securities remaining available for future issuance” includes shares available under our 2014 Equity Incentive Plan.
Unregistered Sales of Equity Securities and Use of Proceeds Sales of Unregistered Securities - none Purchase of Equity Securities - none Equity Compensation Plan Information The following table provides information about our equity compensation plan as of December 31, 2023. Number of Weighted Securities to Average be Issued Exercise Price Number of Upon Exercise of Securities of Outstanding Outstanding Remaining Options, Options, Available for Warrants and Warrants and Future Issuance Plan Category Rights Rights (1) Equity compensation plans approved by security holders 8,695,308 $ 12.64 3,849,804 Equity compensation plans not approved by security holders — — — Total 8,695,308 $ 12.64 3,849,804 (1) The amount appearing under “Number of securities remaining available for future issuance” includes shares available under the Company’s 2023 Equity Incentive Plan (the “2023 Plan”).
During the year ended December 31, 2022, we used $21,170,816 of cash for investing activities, which included $16,500,000, in payments made towards our $30,000,000 technology license fee commitment (as discussed in Note 7), $2,300,000 for the purchase price for the Moviynt acquisition (as discussed in Note 2), $1,723,622 for purchases of manufacturing equipment and product mold tooling; $499,031 in patent and trademark expenditures; and a further investment of $125,000 in the purchase of software operating license upgrades for our smart glasses platform.
During the year ended December 31, 2023, we used $19,280,966 of cash for investing activities, which included $10,500,000 in further payments made towards our technology license fee commitment with Atomistic, as discussed in Note 7, $5,323,483 for purchases of manufacturing equipment and leasehold improvement expenditures primarily related to our waveguide expansion project; a $2,500,000 investment in preferred shares of Atomistic, as discussed in Note 2; $632,483 in patent and trademark expenditures; a further investment of $125,000 in the purchase of software operating license upgrades for our smart glasses platform; and an additional $200,000 of investments in private corporations as discussed in Note 9.
Software development expenses to determine technical feasibility before final development and ongoing maintenance are not capitalized and are included in research and development costs. Year Ended % of Year Ended % of Dollar % Increase December 31, 2021 Total Sales December 31, 2020 Total Sales Change (Decrease) Research and Development $ 11,674,954 89 % $ 7,568,074 65 % $ 4,106,880 54 % Research and development costs for the year ended December 31, 2021, increased by $4,106,880 or 54% as compared to 2020.
Software development expenses to determine technical feasibility before final development and ongoing maintenance are not capitalized and are included in research and development expenses. Year Ended % of Year Ended % of Dollar % Increase December 31, 2023 Total Sales December 31, 2022 Total Sales Change (Decrease) Research and Development $ 12,339,534 102 % $ 12,676,688 107 % $ (337,154) (3) % Research and development expenses for the year ended December 31, 2023, decreased by $337,154, or 3%, compared to the comparable period in 2022.
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities Market for our Common Stock Our common stock is listed on the NASDAQ Capital Market under the symbol “VUZI”.
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities Holders of Record As of April 15, 2024, there were 64 holders of record of our common stock.
Net changes in working capital items were $2,544,394 for the year ended December 31, 2022, with the largest factors resulting from a $2,052,376 increase in trade accounts receivables and other accrued receivables and a decrease of $591,784 in net trade payables and accrued expenses, partially offset by a $98,988 decrease in inventory and vendor prepayments.
Net changes in working capital items were $1,882,446 for the year ended December 31, 2023, with the largest factors resulting from a $1,480,923 increase in trade accounts receivable, net of reserve, and accrued revenue in excess of billings; a $1,495,653 decrease in inventory and vendor prepayments; and a $1,104,787 decrease in trade accounts payable and accrued expenses.
General and administrative costs include professional fees, investor relations (IR) costs, salaries and related stock compensation, travel costs, office and rental costs. Year Ended % of Year Ended % of Dollar % Increase December 31, 2021 Total Sales December 31, 2020 Total Sales Change (Decrease) General and Administrative $ 22,502,833 171 % $ 6,915,213 60 % $ 15,587,620 225 % General and administrative costs for the year ended December 31, 2021, increased by $15,587,620 or 225% as compared 2020.
General and administrative expenses include professional fees, investor relations (IR) costs, salaries and related stock compensation, travel costs, office and rental costs. Year Ended % of Year Ended % of Dollar % Increase December 31, 2023 Total Sales December 31, 2022 Total Sales Change (Decrease) General and Administrative $ 18,592,185 153 % $ 21,038,562 178 % $ (2,446,377) (12) % General and administrative expenses for the year ended December 31, 2023 decreased by $2,446,377, or 12% compared to the comparable period in 2022.
As of December 31, 2022, we had current assets of $91,241,241 as compared to current liabilities of $15,277,358 which resulted in a positive working capital position of $75,963,883. As of December 31, 2021, we had a working capital position of $132,994,189.
As of December 31, 2023, we had current assets of $41,500,411 as compared to current liabilities of $5,216,152, which resulted in a positive working capital position of $36,284,259. As of December 31, 2022, we had a working capital position of $75,354,727.
Revenue Recognition The Company adopted the guidance on Revenue from Contracts with Customers under FASB ASC Topic 606, “Revenue from Contracts with Customers”, as of January 1, 2018. Product sales represent the majority of the Company’s revenue.
The unamortized software development costs remaining were valued (net of accumulated amortization) at $361,111 as of December 31, 2023. Management believes that this value is recoverable. Revenue Recognition The Company adopted the guidance on Revenue from Contracts with Customers under FASB ASC Topic 606, “Revenue from Contracts with Customers”, as of January 1, 2018.
Software Development Costs The Company capitalizes the costs of obtaining and developing its software once technological feasibility has been determined by management or of purchased software solutions when placed into service. Such costs are accumulated and capitalized. These projects could take several years to complete. The capitalized costs are then amortized over 3 years on a straight-line basis.
Such costs are accumulated and capitalized. These projects could take several years to complete. The capitalized costs are then amortized over 3 years on a straight-line basis. Unsuccessful or discontinued software projects are written off and expensed in the fiscal period where the application is abandoned or discontinued.
Costs to acquire a business may include, but are not limited to, fees for accounting, legal and valuation services, and are expensed as incurred in the Consolidated Statements of Income. 38 Table of Contents Variable Interest Entities We determine at the inception of each arrangement whether an entity in which we have made an investment or in which we have other variable interests is considered a variable interest entity (VIE).
It presumes that a Company will continue normal business operations into the future. Variable Interest Entities We determine at the inception of each arrangement whether an entity in which we have made an investment or in which we have other variable interests is considered a variable interest entity (VIE). We consolidate VIEs when we are the primary beneficiary.
The following table reflects the major components of our sales: Year Ended % of Year Ended % of Dollar % Increase December 31, 2021 Total Sales December 31, 2020 Total Sales Change (Decrease) Sales of Smart Glasses $ 12,784,600 97 % $ 10,081,209 87 % $ 2,703,391 27 % Sales of Engineering Services 380,333 3 % 1,500,287 13 % (1,119,954) (75) % Total Sales $ 13,164,933 100 % $ 11,581,496 100 % $ 1,583,437 14 % Sales of Smart Glasses products rose by $2,703,391 or 27% in the year ended December 31, 2021, primarily as a result of continued growth of our M400 model and M4000 Smart Glasses sales, as compared to the same period in 2020.
The following table reflects the major components of our sales: Year Ended % of Year Ended % of Dollar % Increase December 31, 2023 Total Sales December 31, 2022 Total Sales Change (Decrease) Sales of Products $ 10,760,352 89 % $ 10,505,763 89 % $ 254,589 2 % Sales of Engineering Services 1,368,787 11 % 1,330,119 11 % 38,668 3 % Total Sales $ 12,129,139 100 % $ 11,835,882 100 % $ 293,257 2 % Sales of products increased by 2% for the year ended December 31, 2023, compared to the same period in 2022.
Other Income (Expense), Net . Total other expense, net was $397,053 for the year ended December 31, 2021 as compared to income of $1,175,292 in the period in 2020.
The increase in this expense is primarily due to the amortization of our technology license related to the Atomistic Agreements, which began on May 12, 2022. Other Income (Expense), Net . Total other income was $2,152,462 for the year ended December 31, 2023, as compared to $1,468,698 in the same period in 2022, an increase of $683,764.
As of December 31, 2022, our principal sources of liquidity consisted of cash and cash equivalents of $72,563,943. Contractual Obligations The following is a summary of our contractual payment obligations as of December 31, 2022: Less than More than Contractual Obligations Total 1 Year 1-3 Years 3-5 Years 5 Years Operating Lease Obligations $ 1,021,753 $ — $ 1,021,753 — — Licensing Fees Commitment 11,500,000 11,500,000 — — — Open Purchase Obligations 8,082,184 8,082,184 — — —
However, management can make no assurance that the Company will be able to raise additional capital, reduce expenses sufficiently, or enter into a strategic transaction on terms acceptable to the Company, or at all. Contractual Obligations The following is a summary of our contractual payment obligations as of December 31, 2023: Less than More than Contractual Obligations Total 1 Year 1-3 Years 3-5 Years 5 Years Operating Lease Obligations $ 324,102 $ 191,120 $ 132,982 — — Licensing Fees Commitment 1,000,000 1,000,000 — — — Open Purchase Obligations 3,569,012 3,569,012 — — —